Technical Analysis for FATE - Fate Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 4.73% | |
| Oversold Stochastic | Weakness | 4.73% | |
| Fell Below 200 DMA | Bearish | -0.13% | |
| 180 Bearish Setup | Bearish Swing Setup | -0.13% | |
| Wide Bands | Range Expansion | -0.13% | |
| Oversold Stochastic | Weakness | -0.13% | |
| 200 DMA Support | Bullish | -8.18% | |
| MACD Bullish Signal Line Cross | Bullish | -8.18% | |
| Wide Bands | Range Expansion | -8.18% | |
| Oversold Stochastic | Weakness | -8.18% |
| Alert | Time |
|---|---|
| 2x Volume Pace | about 4 hours ago |
| 1.5x Volume Pace | about 4 hours ago |
| Rose Above Previous Day's High | about 4 hours ago |
| 200 DMA Resistance | about 4 hours ago |
| 10 DMA Resistance | about 4 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 06/07/2024
Fate Therapeutics, Inc. Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Stem Cell Hematologic Malignancies Hematopoietic Stem Cell Induced Stem Cells Adult Stem Cell Blood Cells Orphan Disease Cord Blood Lysosomal Storage Disorder Lysosomal Storage Disorders Muscular Dystrophies Umbilical Cord
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.83 |
| 52 Week Low | 1.63 |
| Average Volume | 2,620,744 |
| 200-Day Moving Average | 4.05 |
| 50-Day Moving Average | 6.16 |
| 20-Day Moving Average | 4.56 |
| 10-Day Moving Average | 3.97 |
| Average True Range | 0.41 |
| RSI (14) | 25.93 |
| ADX | 36.3 |
| +DI | 14.13 |
| -DI | 31.02 |
| Chandelier Exit (Long, 3 ATRs) | 5.57 |
| Chandelier Exit (Short, 3 ATRs) | 4.82 |
| Upper Bollinger Bands | 5.96 |
| Lower Bollinger Band | 3.16 |
| Percent B (%b) | 0.19 |
| BandWidth | 61.53 |
| MACD Line | -0.66 |
| MACD Signal Line | -0.67 |
| MACD Histogram | 0.0099 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.05 | ||||
| Resistance 3 (R3) | 4.04 | 3.93 | 3.99 | ||
| Resistance 2 (R2) | 3.93 | 3.84 | 3.93 | 3.97 | |
| Resistance 1 (R1) | 3.81 | 3.78 | 3.76 | 3.82 | 3.95 |
| Pivot Point | 3.70 | 3.70 | 3.67 | 3.70 | 3.70 |
| Support 1 (S1) | 3.58 | 3.61 | 3.53 | 3.59 | 3.45 |
| Support 2 (S2) | 3.47 | 3.55 | 3.47 | 3.43 | |
| Support 3 (S3) | 3.35 | 3.47 | 3.41 | ||
| Support 4 (S4) | 3.36 |
